Utilizing diversity-oriented synthesis in antimicrobial drug discovery

Future Medicinal Chemistry

Volumn 6, Issue 17, 2014, Pages 1927-1942

  Comer, Eamon ^a   Duvall, Jeremy R ^a   Dupont Lee, Maurice ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

chemical complexity; diversity oriented synthesis; drug discovery; hepatitis C virus; infectious disease; malaria; orthopoxviruses; Trypanosoma cruzi

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; MOLECULAR LIBRARY;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC50; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY; COMMUNICABLE DISEASES; DRUG EFFECTS; DRUG SCREENING; GRAM POSITIVE BACTERIUM; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR LIBRARY; ORTHOPOXVIRUS; PHARMACOLOGY; PLASMODIUM FALCIPARUM; THERAPEUTIC USE; TRYPANOSOMA CRUZI;

ANTI-INFECTIVE AGENTS; BIOLOGICAL PRODUCTS; COMMUNICABLE DISEASES; DRUG EVALUATION, PRECLINICAL; GRAM-POSITIVE BACTERIA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ORTHOPOXVIRUS; PLASMODIUM FALCIPARUM; SMALL MOLECULE LIBRARIES; TRYPANOSOMA CRUZI;

EID: 84919782378     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.111     Document Type: Review

References (52)

1. O'Brien C, Henrich PP, Passi N, Fidock DA. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr. Opin. Infect. Dis. 24, 570-577 (2011
2. Butler MS, Cooper MA. Antibiotics in the clinical pipeline. J. Antibiot. 64, 413-425 (2011
3. Berdy J. Thoughts and facts about antibiotics: where we are now and where we are heading. J. Antibiot. 65, 385-395 (2012
4. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007
5. Kogej T, Blomberg N, Greasley P. Big pharma screening collections: more of the same or unique libraries?. The AstraZeneca-Bayer Pharma AG case. Drug Discov Today 18, 19-20 (2013
6. Prieto J, Calvo A, Gomez-Lus ML. Antimicrobial resistance: a class effect?. J. Antimicrob. Chemother. 50, 7-12 (2002
7. Charman SA, Arbe-Barnes S, Bathurst IC et al. Synthetic ozonide drug candidate OZ439 offers new hope for a singledose cure of uncomplicated malaria. Proc. Natl Acad. Sci. USA 108, 4400-4405 (2011
8. Dandapani S, Marcaurelle LA. Accessing new chemical space for 'undruggable' targets. Nat. Chem. Bio. 6(12), 861-863 (2010
9. Galloway WRJD, Bender A, Welch M, Spring DR. The discovery of antibacterial agents using diversity-oriented synthesis. Chem. Commun. (Camb.) 18, 2446-2462 (2009
10. Nielsen TE, Schreiber SL. Towards the optimal screening collection: a synthesis strategy. Angew. Chem. Int. Ed. 47, 48-45 (2008
11. Diversity-Oriented Synthesis: Basics and Applications in Organic Synthesis. Trabocchi A (Ed.) John Wiley & Sons Inc., Hoboken, NJ, USA (2013
12. Clemons PA, Wilson JA, Dan?ík V et al. Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. Proc. Natl Acad. Sci. USA 108, 6817-6822 (2011
13. Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability, are too many aromatic rings a liability in drug design?. Drug Discov. Today 14, 1011-1020 (2009
14. Luker T, Alcaraz L, Chohan KK et al. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. Bioorg. Med. Chem. Lett. 21, 5673-5679 (2011
15. World Health Organization. Research priorities for Chagas disease, human Aftrican Trypanosomiasis and Leishmaniasis. World Health Organ. Tech. Rep. Ser. 975, 1-116 (2012
16. Clayton J. Chagas disease 101. Nature 465, S4-S5 (2010
17. Dandapani S, Germain AR, Jewett I et al. Diversity-oriented synthesis yields a new drug lead for treatment of Chagas disease. ACS Med. Chem. Lett. 5, 149-153 (2014
18. Over B, McCarren P, Artursson P et al. Impact of stereospecific intramolecular hydrogen-bonding on cell permeability and physicochemical properties. J. Med. Chem. 57(6), 2746-2754 (2014
19. Pandya BA, Dandapani S, Duvall JR et al. Practical asymmetric synthesis of ?-hydroxy ?-amino acids via complimentary aldol reactions. Tetrahedron 67, 6131-6137 (2011
20. Marcaurelle LA, Comer E, Dandapani S et al. An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J. Am. Chem. Soc. 132, 16962-16976 (2010
21. Fitzgerald ME, Mulrooney CA, Duvall JR et al Build/couple/pair strategy for the synthesis of stereochemically diverse macrolactams via head-to-tail cyclization. ACS Comb. Sci. 14, 89-96 (2012
22. WHO. World Malaria Report. WHO Press, Geneva, Switzerland (2012
23. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar. J. 12, 187 (2013
24. Ekland EH, Fidock DA. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int. J. Parasitol. 38, 743-747 (2008
25. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TNC, Willis P. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS ONE 8, e62906 (2013
26. Smithson DC, Armand Guiguemde W, Guy RK. Antimalarials. Burger's Medicinal Chemistry and Drug Discovery. John Wiley & Sons, Inc. (2010
27. Rottmann M, McNamara C, Yeung BKS et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329(5996), 1175-1180 (2010
28. Yeung BKS, Zou B, Rottmann M et al. Spirotetrahydro β-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J. Med. Chem. 53(14), 5155-5164 (2010
29. Van Pelt-Koops JC, Pett HE, Graumansa W et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob. Agents Chemother. 56, 3544-3548 (2012
30. Spillman NJ, Allen RJW, McNamara CW et al Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13, 227-237 (2013
31. Heidebrecht RW Jr, Mulrooney C, Austin CP, Barker RH Jr et al. Diversity-oriented synthesis yields a novel lead for the treatment of malaria. ACS Med. Chem. Lett. 3(2), 112-117 (2012
32. Antibiotic Resistance Threats in the United States. US Department of Health and Human Services Centers for Disease Control and Prevention, 1-114 (2013
33. Thomas GL, Spandl RJ, Glansdorp FG et al. Anti-MRSA agent discovery using diversity-oriented synthesis. Angew. Chem. Int. Ed. 47, 2808-2812 (2008
34. Johnson JS, Evans DA. Chiral bis(oxazoline) copper(II) complexes: versatile catalysts for enantioselective cycloaddition, Aldol, Michael, and carbonyl ene reactions. Acc. Chem. Res. 33, 325-335 (2000
35. Reed KD, Melski JW, Graham MB et al. The detection of monkeypox in humans in the Western hemisphere. N. Engl. J. Med. 350, 342-350 (2004
36. Fenner F. A successful eradication campaign. Global eradication of smallpox. Rev. Infect. Dis. 4, 916-930 (1982
37. Quenelle DC, Prichard MN, Keith KA et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51, 4118-4124 (2007
38. Huggins J, Goff A, Hensley L et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53, 2620-2625 (2009
39. Jordan R, Goff A, Frimm A et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53, 1817-1822 (2009
40. Andrei G, Gammon DB, Fiten P et al. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80, 9391-9401 (2006
41. Dower K, Filone CM, Hodges EN et al. Identification of a pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis library. J. Virol. 86, 2632-2640 (2012
42. Dower K, Rubins KH, Hensley LE, Connor JH. Development of vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. Antiviral Res. 91, 72-80 (2001
43. Lou S, Taoka BM, Ting A, Schaus SE. Asymmetric Mannich reaction of beta-keto esters with acyl imines catalyzed by cinchona alkaloids. J. Am. Chem. Soc. 127, 11256-11257 (2005
44. Lou S, Dai P, Schaus SE. Asymmetric Mannich reaction of dicarbonyl compounds with alpha-amidosulfones catalyzed by cinchona alkaloids and synthesis of chiral dihydropyrimidones. J. Org. Chem. 72, 9998-10008 (2007
45. Brown LE, Dai P, Porco JA Jr, Schaus SE. Gold catalyzed cyclization of alkyne-tethered dihydropyrimidones. Org. Lett. 13, 4228-4231 (2011
46. Alter MJ Epidemiology of hepatitis C. Hepatology 43, S207-S220 (2006
47. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 26, S62-S65 (1997
48. "FDA approves Sovaldi for chronic hepatitis C". FDA New Release. U.S. Food and Drug Administration. www.fda.gov/newsevents/newsroom/pressannouncements/ucm377888.htm
49. Waldman R. "Gilead's HCV drug sofosbuvir approved by the FDA but accessible for how many?.". Doctors of the World. (2014).http://doctorsoftheworld.org/wp-content/uploads/2013/07/Gileads-HCV-drug-sofosbuvir-approved-but-accessible-forhow-many-09DEC2013.pdf
50. Peng LF, Kim SS, Matchacheep S, Lei X et al. Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen. Antimicrob. Agents Chemother. 51, 3756-3759 (2007
51. Kim SS, Peng LF, Lin W et al. A cell-based, high-throughput screen for small molecule regulators of HCV replication. Gastroenterology 132, 311-320 (2007
52. Lei X, Zaarur N, Sherman MY, Porco JA Jr. Stereocontrolled synthesis of a complex library via elaboration of angular epoxyquinol scaffolds. J. Org. Chem. 70, 6474-6483 (2005